Akeso(09926.HK): Grant of Share Options and Restricted Share Units
NewTimeSpace News: On 24 July 2026, Akeso(09926.HK) issued an announcement. The Company granted 3,603,500 share options to 167 grantees at an exercise price of HK$99.50 per share. The share options carry a 10-year validity period and a 48-month vesting schedule, and grantees are required to meet individual performance targets for vesting eligibility.
Separately, 1,648,500 restricted share units with a nil purchase price were granted to 162 grantees, subject to identical performance targets and a 48-month vesting period.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- AKESO (09926.HK): Completes 20m-share placing, nets HK$1.94bn
- Biotech Index Hits a Year-to-Date High as Innovative Drug and CXO Names Rally; CSOP Hang Seng Biotech ETF (3174.HK) Gains 3.18% and Is Up 17.93% Year-to-Date
- AKESO (09926.HK): HARMONi-2 interim analysis of ivonescimab meets key secondary OS endpoint with statistical significance and clinical benefit
- AKESO (09926.HK): NMPA Approves Third Indication of Ivonescimab (PD-1/VEGF) for First-Line Treatment of Advanced Squamous NSCLC
- AKESO(09926.HK): Qiyoukang® (Gumokimab) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis
